| Ticker: | TERN |
| Current Price: | $52.95 |
| % Daily Change: | -0.03% |
| Volume (1,000s): | 6,331.48 |
| Average Volume (1,000s): | 5,919.00 |
| Market Cap (M): | $6,116.85 |
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs.